Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genfit SA ( (GNFT) ) has issued an announcement.
On October 30, 2025, GENFIT announced its decision to voluntarily delist its American Depositary Shares (ADSs) from the Nasdaq Global Select Market, effective before November 20, 2025. This strategic move aims to simplify the company’s corporate structure and enhance operational efficiency, while maintaining its primary listing on Euronext Paris. The delisting will not affect GENFIT’s commitment to high standards of corporate governance and transparency, nor will it impact its accounting standards. The company will continue to comply with French and European financial regulations, and the delisting process involves filing necessary forms with the U.S. Securities and Exchange Commission.
The most recent analyst rating on (GNFT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Genfit SA stock, see the GNFT Stock Forecast page.
Spark’s Take on GNFT Stock
According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.
Genfit SA’s overall score reflects a strong financial recovery with improved revenue and profitability. However, the stock’s valuation is a concern due to a negative P/E ratio and no dividend yield. Technical indicators suggest a stable outlook, but caution is advised given the valuation challenges.
To see Spark’s full report on GNFT stock, click here.
More about Genfit SA
GENFIT is a biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases, including Acute on-chronic Liver Failure (ACLF) and Primary Biliary Cholangitis (PBC). The company has a strong R&D portfolio and has successfully developed and commercialized Iqirvo® (elafibranor) for PBC. GENFIT is also involved in diagnostics with products like NIS2+® for detecting Metabolic dysfunction-associated steatohepatitis (MASH). Headquartered in Lille, France, GENFIT operates globally with offices in Paris, Zurich, and Cambridge, MA.
Average Trading Volume: 5,486
Technical Sentiment Signal: Buy
Current Market Cap: $212.1M
See more insights into GNFT stock on TipRanks’ Stock Analysis page.